Pembrolizumab for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 May 2021: Trial registered, NCT04895358
  2. 18 Jun 2021: Trial started, NCT04895358

The trials

NCT04895358: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

State
Under way
Phase
Phase 3
People
342 taking part
Started
18 Jun 2021
Primary completion
24 Apr 2026
Arms
Pembrolizumab + Chemotherapy
Results
None posted
  1. 20 May 2021: Trial registered
  2. 18 Jun 2021: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Keytruda, Keytruda qlex component pembrolizumab, Pembrolizumab 200 mg, Pembrolizumab Injection [Keytruda], Pembrolizumab SC.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.